Cadrenal Therapeutics FY2024 net loss $10.7M; cash $10.0M; Abbott collaboration for Phase 3 tecarfarin trial

Cadrenal Therapeutics, Inc.

Net loss of $10.7M for FY2024 (vs $8.4M in 2023); G&A expenses nearly doubled to $6.8M.
Cash and equivalents of $10.0M as of Dec 31, 2024, up from $8.4M year-end 2023; ~1.8M shares outstanding.
Collaboration with Abbott (NYSE: ABT) to support pivotal Phase 3 TECH-LVAD trial of tecarfarin.
FDA Type D meeting in Feb 2025 provided guidance for tecarfarin Phase 3 trial design; FDA requested full study synopsis.
Appointed Dr. James J. Ferguson as CMO and Jeff Cole as COO; received ODD for tecarfarin in LVAD patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.